 "reddy, dr reddy's")
Dr. Reddy’s Laboratories (DRL) is likely to leverage its relationship with existing and new partners to continue the momentum of product launches in the regulated markets. The company has launched only three new products during 2015 when compared to 14 launches in 2014.
This sharp decline is due to a series of inspections and warning letters from the US Food and Drug Administration (FDA). However, the numbers picked up in the last year with around ten launches.
To see further rise in new launches this year, DRL might look towards strategic partners like Gland Pharma or subsidiaries such as Promius Pharma to
